{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:22:01Z","timestamp":1794482521806,"version":"4.9.1"},"reference-count":29,"publisher":"American Association for Cancer Research (AACR)","issue":"5","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA272296"],"award-info":[{"award-number":["P01CA272296"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["B-cell Lymphoma Moonshot Program"],"award-info":[{"award-number":["B-cell Lymphoma Moonshot Program"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Large B-cell lymphomas (LBCL) are a clinically and molecularly diverse group of malignancies with a rapidly evolving therapeutic landscape that has introduced new areas of clinical need, such as post-CD19 chimeric antigen receptor T (CART19) progression. Patient-derived xenograft (PDX) models are an important tool for mechanistic studies and preclinical evaluation of new therapies and can be generated from a variety of clinical contexts that capture tumor-intrinsic resistance mechanisms. We therefore undertook a comprehensive effort to generate PDX models that encompass the molecular landscape of LBCLs and include important clinical scenarios for new drug development. Here, we describe the first 48 models within this publicly available repository, capturing the transcriptional and genetic subsets of LBCL. These models also include 23 generated from post-CART19 progression patient biopsies, which reproduce patterns of progression driven by CD19 mutation or expression loss, as well as tumor cell\u2013intrinsic CART19 resistance that we validated in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Here, we describe X-LYMPH (Xenografts of Lymphoma), a publicly available and molecularly annotated PDX repository that captures the heterogeneity of LBCL. X-LYMPH includes models of CAR T-cell resistance, providing a shared foundation for mechanistic research and therapeutic development for lymphomas.<\/jats:p>\n                    <jats:p>See related commentary by Evgin and Steidl, p. 655<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-26-0005","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T18:01:51Z","timestamp":1782324111000},"page":"829-844","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3870-2679","authenticated-orcid":false,"given":"Haopeng","family":"Yang","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2838-5961","authenticated-orcid":false,"given":"Kotaro","family":"Arita","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4307-6446","authenticated-orcid":false,"given":"Kevin","family":"Bowman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."},{"name":"2University of Texas MD Anderson Cancer Center UT Health Houston Graduate School of Biological Sciences, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1153-2294","authenticated-orcid":false,"given":"Dai","family":"Chihara","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5121-5234","authenticated-orcid":false,"given":"Jared","family":"Henderson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7590-7373","authenticated-orcid":false,"given":"Griffin","family":"Rost","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4878-9815","authenticated-orcid":false,"given":"Estela","family":"Rojas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2223-2121","authenticated-orcid":false,"given":"Sydney","family":"Parsons","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5449-7556","authenticated-orcid":false,"given":"Priya","family":"Lakra","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8373-5622","authenticated-orcid":false,"given":"Aneela Syeda","family":"Abedin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-4914","authenticated-orcid":false,"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-1459","authenticated-orcid":false,"given":"Paolo","family":"Strati","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-8610","authenticated-orcid":false,"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1844-5548","authenticated-orcid":false,"given":"Luis E.","family":"Fayad","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1646-813X","authenticated-orcid":false,"given":"Swaminathan P.","family":"Iyer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3564-8697","authenticated-orcid":false,"given":"Maria Alma","family":"Rodriguez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8788-7243","authenticated-orcid":false,"given":"Fredrick B.","family":"Hagemeister","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7082-1846","authenticated-orcid":false,"given":"Luis","family":"Malpica","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7219-5562","authenticated-orcid":false,"given":"Hun","family":"Lee","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-6586","authenticated-orcid":false,"given":"Laura K.","family":"Hilton","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03sfybe47","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Cancer 3 Centre for Lymphoid Cancer, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-5947","authenticated-orcid":false,"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03sfybe47","id-type":"ROR","asserted-by":"publisher"}],"name":"BC Cancer 3 Centre for Lymphoid Cancer, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7311-0065","authenticated-orcid":false,"given":"R. Eric","family":"Davis","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9524-3990","authenticated-orcid":false,"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1824-2337","authenticated-orcid":false,"given":"Jason R.","family":"Westin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5566-0864","authenticated-orcid":false,"given":"Giorgio","family":"Inghirami","sequence":"additional","affiliation":[{"name":"4Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5956-452X","authenticated-orcid":false,"given":"Francisco","family":"Vega","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 5 Department of Hematopathology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6309-9472","authenticated-orcid":false,"given":"Michael R.","family":"Green","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma, , Houston, Texas."},{"name":"2University of Texas MD Anderson Cancer Center UT Health Houston Graduate School of Biological Sciences, Houston, Texas."},{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 6 Department of Hematopoietic Biology and Malignancy, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"2026090303083249200_bib1","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO-25-00925","article-title":"Five-year outcomes of the POLARIX study comparing Pola-R-CHP and R-CHOP in patients with diffuse large B-cell lymphoma","volume":"43","author":"Morschhauser","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026090303083249200_bib2","doi-asserted-by":"crossref","first-page":"103605","DOI":"10.1016\/j.xpro.2025.103605","article-title":"Protocol to identify small-molecule inhibitors against cancer drug resistance","volume":"6","author":"Wei","year":"2025","journal-title":"STAR Protoc"},{"key":"2026090303083249200_bib3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ccell.2016.06.008","article-title":"The public repository of xenografts enables discovery and randomized phase II-like trials in mice","volume":"30","author":"Townsend","year":"2016","journal-title":"Cancer cell"},{"key":"2026090303083249200_bib4","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood-2015-09-672352","article-title":"Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"2026090303083249200_bib5","doi-asserted-by":"crossref","first-page":"102029","DOI":"10.1016\/j.xcrm.2025.102029","article-title":"A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities","volume":"6","author":"Fiore","year":"2025","journal-title":"Cell Rep Med"},{"key":"2026090303083249200_bib6","doi-asserted-by":"crossref","first-page":"101225","DOI":"10.1016\/j.jpha.2025.101225","article-title":"The latest progress of personalized drug screening and therapy research for common clinical tumors through the PDX model platform","volume":"15","author":"Yuan","year":"2025","journal-title":"J Pharm Anal"},{"key":"2026090303083249200_bib7","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026090303083249200_bib8","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ccell.2025.06.002","article-title":"Large B cell lymphoma microenvironment archetype profiles","volume":"43","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"key":"2026090303083249200_bib9","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3324\/haematol.2020.274258","article-title":"Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma","volume":"107","author":"Ma","year":"2022","journal-title":"Haematologica"},{"key":"2026090303083249200_bib10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"2026090303083249200_bib11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"2026090303083249200_bib12","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"key":"2026090303083249200_bib13","doi-asserted-by":"crossref","first-page":"eeav5599","DOI":"10.1126\/scitranslmed.aav5599","article-title":"Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B-cell lymphoma","volume":"11","author":"Jain","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026090303083249200_bib14","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026090303083249200_bib15","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"key":"2026090303083249200_bib16","doi-asserted-by":"crossref","first-page":"e001150","DOI":"10.1136\/jitc-2020-001150","article-title":"Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026090303083249200_bib17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer cell"},{"key":"2026090303083249200_bib18","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","article-title":"Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction","volume":"10","author":"Singh","year":"2020","journal-title":"Cancer Discov"},{"key":"2026090303083249200_bib19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","article-title":"Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"2026090303083249200_bib20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2025-107","article-title":"CAR-T efficacy in large B-cell lymphoma is shaped by neoantigen-driven epitope spreading and limited by HLA loss and genomic instability","volume":"146","author":"Savid-Frontera","year":"2025","journal-title":"Blood"},{"key":"2026090303083249200_bib21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.2021015008","article-title":"Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma","volume":"140","author":"Jain","year":"2022","journal-title":"Blood"},{"key":"2026090303083249200_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"2026090303083249200_bib23","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc2306105","article-title":"Cell-of-Origin subtypes and therapeutic benefit from polatuzumab vedotin","volume":"389","author":"Palmer","year":"2023","journal-title":"N Engl J Med"},{"key":"2026090303083249200_bib24","first-page":"2493","article-title":"Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population","volume":"141","author":"Alduaij","year":"2023","journal-title":"Blood"},{"key":"2026090303083249200_bib25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy","volume":"37","author":"Sha","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026090303083249200_bib26","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","article-title":"Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: the randomized GUIDANCE-01 trial","volume":"41","author":"Zhang","year":"2023","journal-title":"Cancer Cell"},{"key":"2026090303083249200_bib27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"key":"2026090303083249200_bib28","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1200\/JCO-25-00399","article-title":"Lisocabtagene maraleucel versus standard of care for second-line relapsed\/refractory large B-cell lymphoma: 3-year follow-up from the randomized, phase III TRANSFORM study","volume":"43","author":"Kamdar","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026090303083249200_bib29","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1002\/hem3.62","article-title":"Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy","volume":"8","author":"Iacoboni","year":"2024","journal-title":"Hemasphere"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-26-0005\/3806387\/bcd-26-0005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/5\/829\/3825031\/bcd-26-0005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/5\/829\/3825031\/bcd-26-0005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:08:45Z","timestamp":1788419325000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/5\/829\/787652\/A-Patient-Derived-Xenograft-Repository-Capturing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,6,24]]},"published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-26-0005","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]}}}